Total (n = 88) | Dropouts (n = 21) | Non-Dropouts (n = 67) | p-value | |
---|---|---|---|---|
Gender [female/male] | 77/11 | 18/3 | 59/8 | 0.777 |
Age [years] | 84.5 (65.0–97.4) | 85.2 (69.4–92.2) | 84.2 (65.0–97.4) | 0.282 |
BMI [kg/m2] | 28.9 (18.1–50.0) | 28.3 (18.1–43.7) | 30.7 (23.4–50.0) | 0.094 |
hs-CRP [mg/L] | 1.9 (0.3–7.9) | 2.0 (0.8–7.9) | 1.9 (0.3–7.6) | 0.413 |
TGF-β signalling | ||||
TGF-β [μg/L] | 33.3 (16.7–73.7) | 39.3 (22.5–58.0) | 32.8 (16.7–73.7) | 0.178 |
TGF-β/GAPDH [-] | 0.53 (0.06–3.36) | 1.07 (0.21–3.36) | 0.52 (0.06–2.66) | 0.016 |
TGF-β RI/GAPDH [-] | 2.05 (0.14–28.81) | 6.41 (1.31–28.81) | 1.90 (0.14–22.39) | <0.001 |
TGF-β RII/GAPDH [-] | 1.67 (0.51–14.85) | 3.00 (0.91–10.80) | 1.59 (0.51–14.85) | 0.099 |
miR–21 [copies/pg RNA] | 2400 (57–5720) | 979 (498–3640) | 2815 (57–4720) | <0.001 |
Co-morbidities | ||||
Obesity [n (%)] | 32 (36.4 %) | 10 (47.6 %) | 22 (32.8 %) | 0.162 |
Hyperlipidemia [n (%)] | 32 (36.4 %) | 3 (14.2 %) | 29 (43.3 %) | 0.016 |
Diabetes Type II [n (%)] | 14 (15.9 %) | 3 (14.3 %) | 11 (16.4 %) | 0.816 |
Hypertension [n (%)] | 70 (79.5 %) | 17 (81.0 %) | 53 (79.1 %) | 0.855 |
Cardiac diseases [n (%)] | 27 (30.7 %) | 7 (33.3 %) | 20 (29.9 %) | 0.763 |
Osteoporosis [n (%)] | 35 (39.8 %) | 9 (42.9 %) | 26 (38.8 %) | 0.741 |
History of cancer [n (%)] | 12 (13.6 %) | 3 (14.3 %) | 9 (13.4 %) | 0.921 |